TRANSFORMATIVE BY NATURE:
Harnessing the Endocannabinoid System for
Our goal is to obtain FDA approval for our lead compound, a non-psychoactive derivative of THC, for a non-hormonal treatment of the genitourinary syndrome of menopause (GSM).
"A non-hormonal treatment may represent a real game-changer in the treatment of the genitourinary syndrome of menopause."
- Irwin Goldstein, M.D., Editor-in-Chief of Sexual Medicine Reviews and past Editor-in-Chief of The Journal of Sexual Medicine, Member of Immugen's Scientific Advisory Board.